Dr Reddys unveils multiple sclerosis drug Dimethyl Fumarate Delayed-Release Capsules
Hyderabad and Princeton: Dr. Reddy's Laboratories Ltd. has recently announced the launch of Dimethyl Fumarate Delayed-Release Capsules, a therapeutic equivalent generic version of Tecfidera® (dimethyl fumarate) Delayed-Release Capsules, approved by the U.S. Food and Drug Administration (USFDA).
Dimethyl fumarate is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Dr. Reddy's Dimethyl Fumarate Delayed-Release Capsules are available in 120 mg and 240 mg capsules in bottle count sizes of 14 and 60 capsules, respectively.
Tecfidera is a trademark of Biogen.
Read also: Dr Reddys launches Dexmedetomidine Injection in US
Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology.
